Neoadjuvant Therapy in Breast Cancer

Introduction:

Breast conserving therapy is becoming more possible with combination neoadjuvant chemotherapy treatments, but the survival advantage of this paradigm is still questionable and unresolved. This Brief examines trends in the neoadjuvant breast cancer market, reasons for widening opinions between key countries and what pharmaceutical companies need to do to increase neoadjuvant therapy administration.

Scope:

* Analysis of primary research of 581 physicians for each stage of breast cancer disease 

* Reasons for differences between the seven major markets 

* Key recommendations for the future of neoadjuvant breast cancer treatments 

* Opinions from leading breast cancer physicians 

Report Highlights:

Widening difference of opinion between US and the rest of the six major markets 

Administration trends of physicians in the seven markets will aid pharmaceutical companies in their targeting strategy of the future 

Present neoadjuvant chemotherapy regimens will change but this is not solely credited to new pipeline drugs 

Reasons to Purchase:

* Understand the key differences between the major geographic markets for neoadjuvant breast cancer therapy 

* Maintain and increase market share by identifying and responding to changing market dynamics and physician expectation 

* Enhance your commercial positioning by understanding expert opinion’s view on the future of therapies in this market 

Publisher: Datamonitor Oncology Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a270